Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for LGND

Stock Name	Ligand Pharmaceuticals Incorporated
Ticker	LGND(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US53220K5048
LEI	5493008K7TB0IKP37H79

Show aggregate LGND holdings

News associated with LGND

Fidelity MSCI Health Care Index ETF -- Insider Buying Index Registering 19.3%: A look at the weighted underlying holdings of the Fidelity MSCI Health Care Index ETF (Symbol: FHLC) shows an impressive 19.3% of holdings on a weighted basis have experienced insider buying within the past six months. Illumina Inc (Symbol: ILMN), which makes up 0.27% of the F - 2025-09-09 10:54:08
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $190.00 Price Target at Oppenheimer: Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) had its price objective upped by Oppenheimer from $167.00 to $190.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s target price points to a potential upside of 13.27% from the stock’s current price. A number of […] - 2025-09-05 05:03:20
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High After Analyst Upgrade: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $167.00 to $190.00. Oppenheimer currently has an outperform rating on the stock. Ligand Pharmaceuticals traded as high as $166.99 and last traded at $166.54, with […] - 2025-09-04 02:18:55
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $157.00 Consensus Price Target from Brokerages: Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last […] - 2025-08-27 02:07:03
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Lowered by Maryland State Retirement & Pension System: Maryland State Retirement & Pension System decreased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,519 shares of the biotechnology company’s stock after selling 844 shares during the period. Maryland State […] - 2025-08-15 04:50:59
Mutual of America Capital Management LLC Reduces Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Mutual of America Capital Management LLC lowered its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% in the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-08-13 06:48:50
Deutsche Bank AG Sells 1,087 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Deutsche Bank AG decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 287,965 shares of the biotechnology company’s stock after selling 1,087 shares during the quarter. Deutsche Bank AG owned 1.49% […] - 2025-08-13 05:19:03
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by Wall Street Zen: Wall Street Zen upgraded shares of Ligand Pharmaceuticals (NASDAQ:LGND – Free Report) from a hold rating to a buy rating in a report published on Saturday. Several other analysts have also weighed in on LGND. Royal Bank Of Canada raised their price objective on Ligand Pharmaceuticals from $155.00 to $185.00 and gave the company an […] - 2025-08-12 04:12:53
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes: (RTTNews) - Ligand Pharmaceuticals Incorporated (LGND) Monday said it intends to privately offer $400 million of senior notes due 2030. - 2025-08-11 08:37:20
LGND Crosses Above Average Analyst Target: In recent trading, shares of Ligand Pharmaceuticals Inc (Symbol: LGND) have crossed above the average analyst 12-month target price of $144.75, changing hands for $146.32/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-08 08:32:29
Insiders Buy the Holdings of TECB ETF: A look at the weighted underlying holdings of the iShares U.S. Tech Breakthrough Multisector ETF (TECB) shows an impressive 14.6% of holdings on a weighted basis have experienced insider buying within the past six months. Ligand Pharmaceuticals Inc (Symbol: LGND), which makes - 2025-07-29 10:45:36
Victory Capital Management Inc. Purchases 13,456 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Victory Capital Management Inc. lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 94.6% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 27,678 shares of the biotechnology company’s stock after acquiring an additional 13,456 shares during the period. Victory Capital Management Inc.’s holdings in Ligand Pharmaceuticals were worth $2,910,000 […] - 2025-07-29 04:23:02
Mutual of America Capital Management LLC Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Mutual of America Capital Management LLC cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.8% during the first quarter, HoldingsChannel.com reports. The fund owned 2,752 shares of the biotechnology company’s stock after selling 110 shares during the period. Mutual of America Capital Management LLC’s holdings in Ligand Pharmaceuticals were […] - 2025-07-24 04:37:00
Arizona State Retirement System Acquires 110 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Arizona State Retirement System raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,407 shares of the biotechnology company’s stock after acquiring an additional 110 shares during the […] - 2025-07-22 07:06:52
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John W. Kozarich sold 934 shares of Ligand Pharmaceuticals stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $125.00, for a total value of $116,750.00. Following the transaction, the director owned 46,456 shares of the company’s stock, valued […] - 2025-07-14 05:38:47
Oregon Public Employees Retirement Fund Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Oregon Public Employees Retirement Fund trimmed its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.3% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 4,342 shares of the biotechnology company’s stock after selling 100 shares during the quarter. Oregon Public Employees Retirement […] - 2025-07-09 05:43:24
Allspring Global Investments Holdings LLC Has $10.14 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Allspring Global Investments Holdings LLC decreased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,419 shares of the biotechnology company’s stock after selling 3,643 shares during the quarter. Allspring Global […] - 2025-07-04 05:06:54
Illinois Municipal Retirement Fund Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Illinois Municipal Retirement Fund increased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,725 shares of the biotechnology company’s stock after purchasing an additional 902 […] - 2025-07-02 05:28:54
State of Alaska Department of Revenue Sells 269 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): State of Alaska Department of Revenue decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 10,470 shares of the biotechnology company’s stock after selling 269 shares during the quarter. State of Alaska Department of Revenue’s holdings in Ligand Pharmaceuticals were worth […] - 2025-06-26 04:44:48
10.2% of VTWV Holdings Seeing Recent Insider Buys: A look at the weighted underlying holdings of the Vanguard Russell 2000 Value (VTWV) shows an impressive 10.2% of holdings on a weighted basis have experienced insider buying within the past six months. NBT Bancorp. Inc. (Symbol: NBTB), which makes up 0.17% of the Vanguard Rus - 2025-06-23 10:36:21
Opal Wealth Advisors LLC Purchases Shares of 305 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Opal Wealth Advisors LLC purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 305 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of other hedge funds have […] - 2025-06-17 04:58:58
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Handelsbanken Fonder AB raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 13.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,658 shares of the biotechnology company’s stock after buying an additional 800 shares during […] - 2025-06-16 05:01:01
Rhumbline Advisers Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Rhumbline Advisers cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 3.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,456 shares of the biotechnology company’s stock after selling 1,989 shares during the period. Rhumbline Advisers’ holdings in Ligand Pharmaceuticals […] - 2025-06-13 04:36:56
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Average Price Target from Analysts: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have updated their coverage on the stock […] - 2025-06-13 02:32:49
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 10,563 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 26.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,401 shares of the biotechnology company’s stock after […] - 2025-06-03 05:13:09
Squarepoint Ops LLC Acquires Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Squarepoint Ops LLC acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 16,799 shares of the biotechnology company’s stock, valued at approximately $1,800,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Smartleaf Asset Management […] - 2025-05-30 06:09:00
Bank of America Corp DE Has $11.51 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Bank of America Corp DE lifted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 107,439 shares of the biotechnology company’s stock after buying an additional 2,533 shares during the quarter. Bank of America Corp DE’s holdings in Ligand Pharmaceuticals […] - 2025-05-23 04:36:48
Jane Street Group LLC Sells 1,083 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): Jane Street Group LLC reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,369 shares of the biotechnology company’s stock after selling 1,083 shares during the quarter. Jane Street Group LLC’s […] - 2025-05-20 04:30:46
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from Analysts: Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) have earned an average recommendation of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock […] - 2025-05-19 02:14:54
The Manufacturers Life Insurance Company Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): The Manufacturers Life Insurance Company increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 9,373 shares of the biotechnology company’s stock after acquiring an additional 779 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Ligand Pharmaceuticals were worth […] - 2025-05-14 05:10:50

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc LGND holdings

Date	Number of LGND Shares Held	Base Market Value of LGND Shares	Local Market Value of LGND Shares	Change in LGND Shares Held	Change in LGND Base Value	Current Price per LGND Share Held	Previous Price per LGND Share Held
2025-11-12 (Wednesday)	2,303	USD 473,520	USD 473,520	-7	USD -8,577	USD 205.61	USD 208.7
2025-11-11 (Tuesday)	2,310	USD 482,097	USD 482,097	0	USD -1,363	USD 208.7	USD 209.29
2025-11-10 (Monday)	2,310	USD 483,460	USD 483,460	0	USD 15,731	USD 209.29	USD 202.48
2025-11-07 (Friday)	2,310	USD 467,729	USD 467,729	0	USD -13,259	USD 202.48	USD 208.22
2025-11-06 (Thursday)	2,310	USD 480,988	USD 480,988	-7	USD 39,878	USD 208.22	USD 190.38
2025-11-05 (Wednesday)	2,317	USD 441,110	USD 441,110	-70	USD -11,107	USD 190.38	USD 189.45
2025-11-04 (Tuesday)	2,387	USD 452,217	USD 452,217	-14	USD -6,950	USD 189.45	USD 191.24
2025-11-03 (Monday)	2,401	USD 459,167	USD 459,167	-14	USD -2,847	USD 191.24	USD 191.31
2025-10-31 (Friday)	2,415	USD 462,014	USD 462,014	0	USD 10,264	USD 191.31	USD 187.06
2025-10-30 (Thursday)	2,415	USD 451,750	USD 451,750	0	USD 6,134	USD 187.06	USD 184.52
2025-10-29 (Wednesday)	2,415	USD 445,616	USD 445,616	0	USD -10,505	USD 184.52	USD 188.87
2025-10-28 (Tuesday)	2,415	USD 456,121	USD 456,121	21	USD 1,333	USD 188.87	USD 189.97
2025-10-27 (Monday)	2,394	USD 454,788	USD 454,788	0	USD 7,158	USD 189.97	USD 186.98

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of LGND by Blackrock for IE00B3VWM098

Show aggregate share trades of LGND

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 SELL -7 209.990 201.540 202.385 USD -1,417 124.15 Loss of -548 on sale
2025-11-06 SELL -7 211.915 186.960 189.456 USD -1,326 122.44 Loss of -469 on sale
2025-11-05 SELL -70 193.070 187.910 188.426 USD -13,190 122.09 Loss of -4,644 on sale
2025-11-04 SELL -14 191.455 186.280 186.797 USD -2,615 121.73 Loss of -911 on sale
2025-11-03 SELL -14 193.020 183.910 184.821 USD -2,587 121.37 Loss of -888 on sale
2025-10-28 BUY 21 188.870 194.440 193.883 USD 4,072 119.95
2025-10-24 SELL -7 186.980 189.600 189.338 USD -1,325 119.21 Loss of -491 on sale
2025-10-15 BUY 42 183.300 185.700 185.460 USD 7,789 116.65
2025-10-02 BUY 7 180.120 182.650 182.397 USD 1,277 115.92
2025-09-30 BUY 14 177.140 177.810 177.743 USD 2,488 115.21
2025-09-17 BUY 647 165.410 169.230 168.848 USD 109,245 113.95
2025-09-11 BUY 20 167.060 169.000 168.806 USD 3,376 113.63
2025-08-21 SELL -5 157.310 157.910 157.850 USD -789 113.37 Loss of -222 on sale
2025-07-31 BUY 15 131.580 137.250 136.683 USD 2,050 113.01
2025-06-30 SELL -10 113.680 115.380 115.210 USD -1,152 111.39 Loss of -38 on sale
2025-06-25 SELL -5 115.720 118.250 117.997 USD -590 111.31 Loss of -33 on sale
2025-06-20 SELL -10 114.070 114.940 114.853 USD -1,149 111.22 Loss of -36 on sale
2025-05-23 BUY 5 101.600 102.110 102.059 USD 510 111.85
2025-05-19 SELL -5 105.310 105.420 105.409 USD -527 112.13 Profit of 34 on sale
2025-05-15 SELL -15 103.470 105.400 105.207 USD -1,578 112.27 Profit of 106 on sale
2025-05-12 SELL -5 106.380 109.200 108.918 USD -545 112.45 Profit of 18 on sale
2025-05-09 SELL -5 104.480 107.150 106.883 USD -534 112.52 Profit of 28 on sale
2025-04-30 SELL -5 109.860 111.480 111.318 USD -557 112.92 Profit of 8 on sale
2025-04-24 SELL -10 108.550 109.240 109.171 USD -1,092 113.07 Profit of 39 on sale
2025-04-17 SELL -5 104.970 106.000 105.897 USD -529 113.47 Profit of 38 on sale
2025-04-15 SELL -15 106.800 107.270 107.223 USD -1,608 113.64 Profit of 96 on sale
2025-04-14 SELL -15 106.590 107.620 107.517 USD -1,613 113.71 Profit of 93 on sale
2025-04-09 SELL -20 103.850 106.350 106.100 USD -2,122 114.07 Profit of 159 on sale
2025-04-07 SELL -35 99.410 102.550 102.236 USD -3,578 114.44 Profit of 427 on sale
2025-04-04 SELL -50 99.570 101.150 100.992 USD -5,050 114.61 Profit of 681 on sale
2025-03-31 BUY 5 105.140 106.370 106.247 USD 531 114.92
2025-03-19 SELL -10 108.030 109.080 108.975 USD -1,090 115.54 Profit of 66 on sale
2025-03-14 SELL -30 106.190 109.250 108.944 USD -3,268 115.88 Profit of 208 on sale
2025-03-13 SELL -10 105.620 109.270 108.905 USD -1,089 116.02 Profit of 71 on sale
2025-03-12 SELL -170 108.090 111.220 110.907 USD -18,854 116.14 Profit of 889 on sale
2025-03-07 SELL -10 114.830 117.100 116.873 USD -1,169 116.41 Loss of -5 on sale
2025-03-06 SELL -15 116.000 116.650 116.585 USD -1,749 116.42 Loss of -2 on sale
2025-03-03 SELL -5 112.180 125.170 123.871 USD -619 116.52 Loss of -37 on sale
2025-02-28 SELL -30 122.230 122.240 122.239 USD -3,667 116.43 Loss of -174 on sale
2025-02-26 SELL -5 115.010 120.720 120.149 USD -601 116.46 Loss of -18 on sale
2025-02-25 SELL -15 118.700 119.590 119.501 USD -1,793 116.43 Loss of -46 on sale
2025-02-18 BUY 25 119.990 121.650 121.484 USD 3,037 115.95
2025-02-13 BUY 5 113.930 115.990 115.784 USD 579 115.83
2025-02-12 BUY 5 111.390 112.660 112.533 USD 563 115.92
2025-02-11 BUY 15 112.770 114.750 114.552 USD 1,718 115.99
2025-02-06 BUY 45 117.840 119.260 119.118 USD 5,360 116.00
2025-01-27 BUY 5 117.280 119.110 118.927 USD 595 115.71
2024-12-30 BUY 25 105.760 109.460 109.090 USD 2,727 116.27
2024-12-06 BUY 20 124.830 127.860 127.557 USD 2,551 115.90
2024-12-05 BUY 5 123.510 124.240 124.167 USD 621 115.64
2024-12-04 BUY 25 120.980 123.000 122.798 USD 3,070 115.45
2024-11-29 BUY 25 121.470 124.340 124.053 USD 3,101 114.74
2024-11-27 BUY 20 122.550 125.000 124.755 USD 2,495 114.06
2024-11-26 BUY 5 124.330 124.440 124.429 USD 622 113.59
2024-11-21 BUY 25 116.550 118.120 117.963 USD 2,949 112.77
2024-11-20 BUY 15 111.560 112.000 111.956 USD 1,679 112.84
2024-11-18 BUY 60 111.670 113.040 112.903 USD 6,774 112.97
2024-11-12 BUY 40 120.740 124.460 124.088 USD 4,964 112.46
2024-11-08 BUY 25 121.250 127.260 126.659 USD 3,166 111.83
2024-11-07 BUY 75 129.900 129.900 129.900 USD 9,742 110.44
2024-11-06 BUY 10 116.900 116.950 116.945 USD 1,169 109.90
2024-10-31 BUY 5 105.700 109.560 109.174 USD 546 110.21
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	SELL	-7	209.990	201.540	202.385	USD -1,417	124.15 Loss of -548 on sale
2025-11-06	SELL	-7	211.915	186.960	189.456	USD -1,326	122.44 Loss of -469 on sale
2025-11-05	SELL	-70	193.070	187.910	188.426	USD -13,190	122.09 Loss of -4,644 on sale
2025-11-04	SELL	-14	191.455	186.280	186.797	USD -2,615	121.73 Loss of -911 on sale
2025-11-03	SELL	-14	193.020	183.910	184.821	USD -2,587	121.37 Loss of -888 on sale
2025-10-28	BUY	21	188.870	194.440	193.883	USD 4,072	119.95
2025-10-24	SELL	-7	186.980	189.600	189.338	USD -1,325	119.21 Loss of -491 on sale
2025-10-15	BUY	42	183.300	185.700	185.460	USD 7,789	116.65
2025-10-02	BUY	7	180.120	182.650	182.397	USD 1,277	115.92
2025-09-30	BUY	14	177.140	177.810	177.743	USD 2,488	115.21
2025-09-17	BUY	647	165.410	169.230	168.848	USD 109,245	113.95
2025-09-11	BUY	20	167.060	169.000	168.806	USD 3,376	113.63
2025-08-21	SELL	-5	157.310	157.910	157.850	USD -789	113.37 Loss of -222 on sale
2025-07-31	BUY	15	131.580	137.250	136.683	USD 2,050	113.01
2025-06-30	SELL	-10	113.680	115.380	115.210	USD -1,152	111.39 Loss of -38 on sale
2025-06-25	SELL	-5	115.720	118.250	117.997	USD -590	111.31 Loss of -33 on sale
2025-06-20	SELL	-10	114.070	114.940	114.853	USD -1,149	111.22 Loss of -36 on sale
2025-05-23	BUY	5	101.600	102.110	102.059	USD 510	111.85
2025-05-19	SELL	-5	105.310	105.420	105.409	USD -527	112.13 Profit of 34 on sale
2025-05-15	SELL	-15	103.470	105.400	105.207	USD -1,578	112.27 Profit of 106 on sale
2025-05-12	SELL	-5	106.380	109.200	108.918	USD -545	112.45 Profit of 18 on sale
2025-05-09	SELL	-5	104.480	107.150	106.883	USD -534	112.52 Profit of 28 on sale
2025-04-30	SELL	-5	109.860	111.480	111.318	USD -557	112.92 Profit of 8 on sale
2025-04-24	SELL	-10	108.550	109.240	109.171	USD -1,092	113.07 Profit of 39 on sale
2025-04-17	SELL	-5	104.970	106.000	105.897	USD -529	113.47 Profit of 38 on sale
2025-04-15	SELL	-15	106.800	107.270	107.223	USD -1,608	113.64 Profit of 96 on sale
2025-04-14	SELL	-15	106.590	107.620	107.517	USD -1,613	113.71 Profit of 93 on sale
2025-04-09	SELL	-20	103.850	106.350	106.100	USD -2,122	114.07 Profit of 159 on sale
2025-04-07	SELL	-35	99.410	102.550	102.236	USD -3,578	114.44 Profit of 427 on sale
2025-04-04	SELL	-50	99.570	101.150	100.992	USD -5,050	114.61 Profit of 681 on sale
2025-03-31	BUY	5	105.140	106.370	106.247	USD 531	114.92
2025-03-19	SELL	-10	108.030	109.080	108.975	USD -1,090	115.54 Profit of 66 on sale
2025-03-14	SELL	-30	106.190	109.250	108.944	USD -3,268	115.88 Profit of 208 on sale
2025-03-13	SELL	-10	105.620	109.270	108.905	USD -1,089	116.02 Profit of 71 on sale
2025-03-12	SELL	-170	108.090	111.220	110.907	USD -18,854	116.14 Profit of 889 on sale
2025-03-07	SELL	-10	114.830	117.100	116.873	USD -1,169	116.41 Loss of -5 on sale
2025-03-06	SELL	-15	116.000	116.650	116.585	USD -1,749	116.42 Loss of -2 on sale
2025-03-03	SELL	-5	112.180	125.170	123.871	USD -619	116.52 Loss of -37 on sale
2025-02-28	SELL	-30	122.230	122.240	122.239	USD -3,667	116.43 Loss of -174 on sale
2025-02-26	SELL	-5	115.010	120.720	120.149	USD -601	116.46 Loss of -18 on sale
2025-02-25	SELL	-15	118.700	119.590	119.501	USD -1,793	116.43 Loss of -46 on sale
2025-02-18	BUY	25	119.990	121.650	121.484	USD 3,037	115.95
2025-02-13	BUY	5	113.930	115.990	115.784	USD 579	115.83
2025-02-12	BUY	5	111.390	112.660	112.533	USD 563	115.92
2025-02-11	BUY	15	112.770	114.750	114.552	USD 1,718	115.99
2025-02-06	BUY	45	117.840	119.260	119.118	USD 5,360	116.00
2025-01-27	BUY	5	117.280	119.110	118.927	USD 595	115.71
2024-12-30	BUY	25	105.760	109.460	109.090	USD 2,727	116.27
2024-12-06	BUY	20	124.830	127.860	127.557	USD 2,551	115.90
2024-12-05	BUY	5	123.510	124.240	124.167	USD 621	115.64
2024-12-04	BUY	25	120.980	123.000	122.798	USD 3,070	115.45
2024-11-29	BUY	25	121.470	124.340	124.053	USD 3,101	114.74
2024-11-27	BUY	20	122.550	125.000	124.755	USD 2,495	114.06
2024-11-26	BUY	5	124.330	124.440	124.429	USD 622	113.59
2024-11-21	BUY	25	116.550	118.120	117.963	USD 2,949	112.77
2024-11-20	BUY	15	111.560	112.000	111.956	USD 1,679	112.84
2024-11-18	BUY	60	111.670	113.040	112.903	USD 6,774	112.97
2024-11-12	BUY	40	120.740	124.460	124.088	USD 4,964	112.46
2024-11-08	BUY	25	121.250	127.260	126.659	USD 3,166	111.83
2024-11-07	BUY	75	129.900	129.900	129.900	USD 9,742	110.44
2024-11-06	BUY	10	116.900	116.950	116.945	USD 1,169	109.90
2024-10-31	BUY	5	105.700	109.560	109.174	USD 546	110.21

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of LGND

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	110,984	0	159,903	69.4%
2025-09-18	117,054	13,457	140,913	83.1%
2025-09-17	81,005	0	103,214	78.5%
2025-09-16	92,697	0	112,565	82.3%
2025-09-15	86,010	12	107,580	79.9%
2025-09-12	68,288	0	104,615	65.3%
2025-09-11	60,509	301	71,159	85.0%
2025-09-10	35,593	223	59,633	59.7%
2025-09-09	101,282	28,400	147,520	68.7%
2025-09-08	32,301	0	42,928	75.2%
2025-09-05	72,289	25,659	90,824	79.6%
2025-09-04	34,071	290	39,292	86.7%
2025-09-03	55,981	3,084	64,953	86.2%
2025-09-02	33,298	1,247	54,732	60.8%
2025-08-29	49,378	1,324	60,183	82.0%
2025-08-28	41,100	1,122	50,668	81.1%
2025-08-27	42,612	533	53,754	79.3%
2025-08-26	30,554	16,905	44,556	68.6%
2025-08-25	52,529	226	57,736	91.0%
2025-08-22	79,217	27,200	96,318	82.2%
2025-08-21	26,493	73	34,681	76.4%
2025-08-20	34,995	100	48,398	72.3%
2025-08-19	34,424	1,314	46,478	74.1%
2025-08-18	57,773	4,412	84,246	68.6%
2025-08-15	110,176	26,500	135,284	81.4%
2025-08-14	88,175	29,505	111,162	79.3%
2025-08-13	106,251	11,400	149,502	71.1%
2025-08-12	1,046,591	263,275	1,291,167	81.1%
2025-08-11	379,969	0	465,623	81.6%
2025-08-08	43,704	1,589	96,370	45.4%
2025-08-07	96,752	7,844	131,275	73.7%
2025-08-06	81,719	0	98,017	83.4%
2025-08-05	31,915	2,291	55,506	57.5%
2025-08-04	27,475	3,500	42,040	65.4%
2025-08-01	43,001	0	53,660	80.1%
2025-07-31	58,147	0	89,224	65.2%
2025-07-30	44,784	6,207	72,410	61.8%
2025-07-29	26,036	0	34,478	75.5%
2025-07-28	21,430	933	37,717	56.8%
2025-07-25	31,566	875	41,560	76.0%
2025-07-24	21,577	1,183	36,717	58.8%
2025-07-23	41,043	6,123	51,663	79.4%
2025-07-22	69,081	1,504	90,344	76.5%
2025-07-21	139,754	6,798	166,003	84.2%
2025-07-18	77,882	8,200	132,441	58.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE